Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$109.45M+232.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oguzhan Atay
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 713
- Beta
- 0.34
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 15.25
Financials
BLLN has only 10 quarterly periods on file — the charts below show the full history available.
Revenue
$109.45M+232.4%Net Income
$8.05MEBITDA
$10.92MFree Cash Flow
$5.09MEPS (diluted)
$0.15Shares Outstanding (diluted)
54.46M+21.8%Operating Expenses
$71.60MCash & Debt
$548.63MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $305.11M | $7.45M | $0.06 |
| 2024 | $152.58M | $-41.57M | $-0.93 |
| 2023 | $71.73M | $-82.68M | $-1.85 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.24
- Implied price
- $4.30
- Return from $98.09
- -46.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.14 — -97.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -55.2% | -53.2% | -51.4% | -49.9% | -48.6% |
| 3.0% | -52.9% | -50.8% | -49.0% | -47.4% | -45.9% |
| 8.0% | -50.7% | -48.4% | -46.5% | -44.8% | -43.3% |
| 13.0% | -48.4% | -46.0% | -44.0% | -42.3% | -40.7% |
| 18.0% | -46.1% | -43.6% | -41.5% | -39.7% | -38.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·5h ago·Negative
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a con…
View source ↗ - News (RSS)seekingalpha·1d ago·Neutral
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials
View source ↗ - Newsseekingalpha.com·1d ago·Neutral
…And GARP Credentials BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average …
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
View source ↗ - Newsprnewswire.com·41d ago·Negative
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.
View source ↗ - Newsprnewswire.com·43d ago·Negative
…rom a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cove…
View source ↗ - Newsfool.com·47d ago·Negative
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.
View source ↗
Earnings
Typical surprise -18.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.15 vs $0.18miss
- Wed, May 6$0.34 vs $0.01beat
- Wed, Mar 4$0.11 vs $0.07beat
- Tue, Dec 9$0.10 vs $0.14miss
- Tue, Oct 7$-0.02 vs $0.14miss
Estimates and results for BLLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLLN officers and directors.
- Bought
- —
- Sold
- $8.4m
0 trades
22 trades
- Ten Bosch John Rodericksold
- Ten Bosch John Rodericksold
- Tsao Davidsold
- Tsao Davidsold
- Tsao Davidsold
- Tsao Davidsold
- Tsao Davidsold
- Tsao Davidsold
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BLLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.